ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis. sBLA accepted for FDA priority review ...

赛诺菲

赛诺菲集团

<p>ACAAI：赛诺菲和再生元的 Dupixent 关键研究达成所有主要和次要终点，减轻过敏性真菌性鼻窦炎的症状和体征。sBLA 已被 FDA 接受进行优先审查</p>

Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

新闻稿：ACAAI：赛诺菲和 Regeneron 的 Dupixent 关键研究达到了所有主要和次要终点，减少了过敏性真菌性鼻窦炎的体征和症状；补充生物制品许可申请被 FDA 接受为优先审查